In addition to aging, MMP1 has been identified as a biomarker for several cancers, pulmonary fibrosis, and potentially Alzheimer’s disease [68–71], whereas STC1 has been identified as a diagnostic and prognostic biomarker for cancers, pulmonary fibrosis, renal ischemia/reperfusion injury, and Alzheimer’s disease [35–40]. Here, STC1 is linked to early-onset autosomal dominant Alzheimer disease.